Savara (SVRA) News
NASDAQ: SVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SVRA news summary
We found 4 recent headlines mentioning Savara (SVRA): 3 in the past week and 4 in the past 30 days, most often from Nasdaq, Seeking Alpha, Investing.com. SVRA is making an outsized move today, down 18.23% at $4.26, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Savara drops after FDA says it will not meet molgramostim BLA action date", was published by Seeking Alpha on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Savara headlines
- Savara drops after FDA says it will not meet molgramostim BLA action dateSeeking Alpha
- Savara Says FDA Likely To Miss Molgramostim Review Deadline(RTTNews) - Savara Inc. (SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced on Friday that the U.S. Food and Drug Administration will not meet the…Nasdaq
- Why is Savara stock plunging today?Investing.com
- Biotech Stocks Facing FDA Decision In November 2026(RTTNews) - The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.NasdaqAGIO, BBIO, CAPR, COGT